Covidien's Restoril Dose Patent Deemed Obvious

Law360, New York (May 6, 2010, 1:11 PM EDT) -- A federal judge has handed victory to defendant URL Pharma Inc. in its battle with Covidien PLC over a generic version of the sleep aid Restoril, rendering the patent Covidien was seeking to enforce obvious.

Judge Stanley R. Chesler of the U.S. District Court for the District of New Jersey on Wednesday found that drug companies would naturally attempt to design a sleep aid using a lower dose of the active ingredient temazepam.

“[URL] has shown that a skilled artisan would have been motivated to try...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.